While the test was conducted in NSCLC, the FDA approval includes existing solid tumor indications for Keytruda. Merck is ...
In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, ...
If you have been watching Merck (MRK) lately, the recent FDA approval for Keytruda QLEX has probably caught your eye. This ...
For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent ...
The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and ...
The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.
Merck & Co., Inc. (NYSE:MRK) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In. Following a decline in revenue ...
Everyday Health on MSN
Blockbuster Cancer Drug Keytruda Now Available as a Time-Saving Shot
Patients taking the immunotherapy drug Keytruda (pembrolizumab) may now have the option to take it as a quick shot instead of ...
FDA approves Keytruda Qlex, a subcutaneous injection version of the widely used cancer therapy Keytruda Patients can now ...
The FDA has approved a new injectable version of cancer drug Keytruda as Merck seeks to protect its market dominance. Here are five things to know: ...
Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...
First pivotal Phase 3 trial to show superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC “These results have the potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback